Evaluating SCUBE-1 as Predictive Biomarker for Hypertension-Mediated Organ Damage: A Comparative Study

Betül Ayça Yamak1, Mustafa Candemir1, Emrullah Kızıltunç1

  • 1Department of Cardiology, Gazi University Faculty of Medicine, 06560 Ankara, Turkey.

PubMed

Insights

Serum signal peptide, CUB domain, and EGF-like domain-containing protein 1 (SCUBE-1) is elevated in hypertension patients with organ damage. Higher SCUBE-1 levels indicate greater hypertension-mediated organ damage (HMOD), suggesting its potential as a biomarker.

Area of Science:

  • Cardiovascular Research
  • Biomarker Discovery
  • Hypertension Studies

Background:

  • Hypertension-mediated organ damage (HMOD) is a major complication affecting cardiac, retinal, and renal systems.
  • Serum signal peptide, CUB domain, and EGF-like domain-containing protein 1 (SCUBE-1) is a novel biomarker associated with vascular pathology.
  • Investigating SCUBE-1's role in detecting HMOD is crucial for patient outcomes.

Purpose of the Study:

  • To explore the relationship between SCUBE-1 levels and HMOD in hypertensive individuals.
  • To assess the diagnostic utility of SCUBE-1 for detecting HMOD in hypertension.

Main Methods:

  • A cross-sectional study involving 115 participants (79 hypertensive, 36 controls).
  • Hypertensive patients were categorized based on the presence or absence of HMOD.
  • SCUBE-1 levels were quantified and analyzed for diagnostic accuracy.

Main Results:

  • Hypertensive patients showed significantly higher SCUBE-1 levels (160.70 ng/mL) than controls (75.64 ng/mL).
  • Patients with HMOD exhibited markedly elevated SCUBE-1 levels (311.27 ng/mL) compared to those without HMOD (142.53 ng/mL).
  • SCUBE-1 demonstrated significant diagnostic potential for cardiac (AUC 0.722), retinal (AUC 0.761), and renal (AUC 0.707) damage.

Conclusions:

  • SCUBE-1 levels are significantly elevated in hypertensive patients, especially those with HMOD.
  • SCUBE-1 shows promise as a valuable biomarker for predicting organ damage in hypertension.
  • Further research can validate SCUBE-1 for clinical application in HMOD assessment.
Abstract